Using Glialia for Treating Persistent Perceptual Postural Dizziness

Recruiting Phase 4 Interventional Study
Persistent Postural Perceptual Dizziness
Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
I.R.C.C.S. Fondazione Santa Lucia · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This pilot study will involve 30 participants recruited from the Santa Lucia Foundation IRCCS, including 20 patients diagnosed with Persistent Perceptual Postural Dizziness (PPPD), and might or might not have previously contracted Sars Cov2 infection. They who will be randomly assigned to receive either the Glialia supplement or placebo. Additionally, 10 control participants who have recovered fro…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria for all groups: -Age between 18 and 65 years. Inclusion criteria for the PPPD-glialia group: * Diagnosis of PPPD; * Recovery from COVID-19 infection or absence of previous infection. Inclusion criteria for the PPPD-placebo group: * Diagnosis of PPPD; * Recovery from COVID-19 …
Contacts

Iole Indovina, PhD

0039 0651501476

i.indovina@hsantalucia.it

CONTACT

Diego Piatti, PT

0039 0651501479

d.piatti@hsantalucia.it

CONTACT